Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (Retraction in: Nature Medicine (2003) 9:9 (1221))

Nature Medicine

Volumn 6, Issue 3, 2000, Pages 332-336

  Kugler, Alexander ^c   Stuhler, Gernot ^a   Walden, Peter ^b   Zöller, Gerhard ^c   Zobywalski, Anke ^a   Brossart, Peter ^a   Trefzer, Uwe ^b   Ullrich, Silke ^c   Müller, Claudia A ^a   Becker, Volker ^c   Gross, Andreas J ^c   Hemmerlein, Bernhard ^c   Kanz, Lothar ^a   Müller, Gerhard A ^c   Ringert, Rolf Hermann ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; DENDRITIC CELL; FOLLOW UP; HUMAN; HYBRID CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; SAFETY; VACCINATION;

AGED; AGED, 80 AND OVER; CANCER VACCINES; CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; HYBRID CELLS; INTERFERON TYPE II; KIDNEY NEOPLASMS; LYMPHOCYTES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; SURVIVAL ANALYSIS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0034100896     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/73193     Document Type: Article

References (16)

1. Jayson, G.C., Middleton, M., Lee, S.M., Ashcroft, L. & Thatcher, N. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer. Br. J. Cancer 78, 366-369 (1998).
2. Lokich, J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am. J. Clin. Oncol. 20, 416-418 (1997).
3. Jantzer, P. & Schendel, D.J. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res. 58, 3078-3086 (1998).
4. Guo, Y. et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263, 518-520 (1994).
5. Stuhler, G. & Walden, P. Recruitment of helper T cells for induction of tumor rejection by cytolytic T lymphocytes. Cancer Immunol. Immunother 39, 342-345 (1994).
6. Gong, J., Chen, D., Kashiwaba, M. & Kufe, D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 3, 558-561 (1997).
7. Wang, J., Saffold, S., Cao, X., Krauss, J. & Chen, W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161, 5516-5524 (1998).
8. Gong, J. et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95, 6279-6283 (1998).
9. Kugler, A. et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br. J. Urol. 82, 487-493 (1998).
10. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
11. Stuhler, G. et al. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc. Natl. Acad. Sci. USA 96, 1532-1535 (1999).
12. Brossart, P. et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93, 4309-4317 (1999).
13. Brossart, P. et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58, 732-736 (1998).
14. Fujita, K. et al. Expression of MUC1 mucins inversely correlate with post-surgical survival of renal cell carcinoma patients. Br. J. Cancer 80, 301-308 (1999).
15. Anichini, A., Mazzocchi, A., Fossati, G. & Parmiani, G. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. J. Immunol. 142, 3692-3701 (1989).
16. Sallusto, F. & Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179, 110-1118 (1994).